Felodipine clinical studies

Revision as of 14:21, 28 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Felodipine}} {{CMG}}; {{AE}} {{SS}} ==Clinical Studies== Felodipine produces dose-related decreases in systolic and diastolic blood pressure as demonstrated in s...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Felodipine
PLENDIL® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Felodipine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Clinical Studies

Felodipine produces dose-related decreases in systolic and diastolic blood pressure as demonstrated in six placebo-controlled, dose response studies using either immediate-release or extended-release dosage forms. These studies enrolled over 800 patients on active treatment, at total daily doses ranging from 2.5 to 20 mg. In those studies felodipine was administered either as monotherapy or was added to beta blockers. The results of the 2 studies with PLENDIL given once daily as monotherapy are shown in the table below:

[1]


References

  1. "PLENDIL (FELODIPINE) TABLET, EXTENDED RELEASE [ASTRAZENECA LP]". Retrieved 28 February 2014.

Template:Calcium channel blockers